Continuous Subcutaneous Insulin Infusion Versus Multiple Dose Insulin Injections in Routine Clinical Practice
Launched by CASTILLA-LA MANCHA HEALTH SERVICE · Jan 3, 2019
Trial Information
Current as of May 21, 2025
Completed
Keywords
ClinConnect Summary
Cross-sectional analysis about effectiveness and safety of continuous subcutaneous insulin infusion compared to multiple dose insulin injections in T1DM adult patients in routine clinical practice.
All clinical variables are gathered from four EMR softwares (Mambrino XXI, Carelink Pro®, Emminens eConecta® and FreeStyle Libre®).
Data analysis is conducted using SPSS (Chicago, IL) statistics software. Results are presented as mean ± SD values or percentages. A paired Student's t-test or a Wilcoxon signed-rank test were used for the analysis of differences. Comparisons between proportions we...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ≥18 years of age.
- • Diagnosed of Type 1 Diabetes Mellitus.
- • Be attended in Ciudad Real General University Hospital.
- • Current treated with CSII (CSII cohort) or MDI (MDI cohort) during ≥6 months.
- Exclusion Criteria:
- • Less than 18 years old.
- • Other types of diabetes mellitus.
About Castilla La Mancha Health Service
The Castilla-La Mancha Health Service (Servicio de Salud de Castilla-La Mancha, SESCAM) is a regional healthcare authority in Spain dedicated to providing high-quality medical services and advancing public health. As a clinical trial sponsor, SESCAM plays a pivotal role in facilitating innovative research initiatives aimed at improving patient outcomes and enhancing medical practices. The organization is committed to ethical standards, regulatory compliance, and collaboration with various stakeholders, including healthcare professionals, researchers, and pharmaceutical companies, to foster the development of new therapies and interventions that address pressing health challenges in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ciudad Real, , Spain
Patients applied
Trial Officials
Jesus Moreno-Fernandez, PhD
Principal Investigator
Castilla-La Mancha Public Health Service.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials